1. Lee JH, An HK, Sohn MG, Kivela P, Oh S. 4, 4′-diaminodiphenyl sulfone (DDS) as an inflammasome competitor. Int J Mol Sci. 2020;21(17):5953.
2. Wang C, Li Q, Li T. Dioscin alleviates lipopolysaccharide-induced acute lung injury through suppression of TLR4 signaling pathways. Exp Lung Res. 2020;46(1-2):11-22.
3. Lee JH, Choi SH, Lee CJ, Oh SS. Recovery of dementia syndrome following treatment of brain inflammation. Dement Geriatr Cogn Dis Extra. 2020;10(1):1-12.
4. Lee J, Lee CJ, Park J, Lee SJ, Choi S. The Neuroinflammasome in Alzheimer’s Disease and Cerebral Stroke. Dementia and Geriatric Cognitive Disorders Extra. 2021;11(2):159-67.
5. Rodrigues TS, De Sá KSG, Ishimoto AY, Becerra A, Oliveira S, Almeida L, et al. Inflammasomes are activated in response to SARS-CoV-2 infection and are associated with COVID-19 severity in patients. J Exp Med. 2021;218(3):e20201707.
6. Beigel JH, Tomashek KM, Dodd LE, Mehta AK, Zingman BS, Kalil AC, et al. Remdesivir for the treatment of Covid-19—preliminary report. N Engl J Med. 2020;383(19):1813-26.
7. Sterne J, Murthy S, Diaz J, Slutsky A, Villar J, Angus D, et al. Association between administration of systemic corticosteroids and mortality among critically ill patients with COVID-19: a meta-analysis. JAMA. 2020;324(13):1330-41.
8. WHO Solidarity Trial Consortium, Pan H, Peto R, Henao-Restrepo A-M, Preziosi M-P, Sathiyamoorthy V, et al. Repurposed antiviral drugs for COVID-19—interim WHO SOLIDARITY trial results. N Engl J Med. 2020;384(6):497-511.
9. Simonovich VA, Burgos Pratx LD, Scibona P, Beruto MV, Vallone MG, Vázquez C, et al. A randomized trial of convalescent plasma in Covid-19 severe pneumonia. N Engl J Med2020. p. NEJMoa2031304.
10. Kelley N, Jeltema D, Duan Y, He Y. The NLRP3 inflammasome: an overview of mechanisms of activation and regulation. Int J Mol Sci. 2019;20(13):3328.
11. O’Donnell JS, Peyvandi F, Martin-Loeches I. Pulmonary immuno-thrombosis in COVID-19 ARDS pathogenesis. Intensive Care Medicine. 2021.
12. Du M, Garcia JG, Christie JD, Xin J, Cai G, Meyer NJ, et al. Integrative omics provide biological and clinical insights into acute respiratory distress syndrome. Intensive care medicine. 2021:1-11.
13. Ichinohe T, Yamazaki T, Koshiba T, Yanagi Y. Mitochondrial protein mitofusin 2 is required for NLRP3 inflammasome activation after RNA virus infection. Proc Natl Acad Sci U S A. 2013;110(44):17963-8.
14. Khan A, Sergi C. SAMHD1 as the potential link between SARS-CoV-2 infection and neurological complications. Front Neurol. 2020;11:562913.
15. Park S, Juliana C, Hong S, Datta P, Hwang I, Fernandes-Alnemri T, et al. The mitochondrial antiviral protein MAVS associates with NLRP3 and regulates its inflammasome activity. J Immunol. 2013;191(8):4358-66.
16. Santos VS, Quintans‐Júnior LJ, De Souza Barboza W, Antunes De Souza Araújo A, Ricardo Martins‐Filho P. Clinical Characteristics and Outcomes in Patients With COVID‐2019 and Leprosy. Journal of the European Academy of Dermatology and Venereology. 2020.
17. Patel BV, Arachchillage DJ, Ridge CA, Bianchi P, Doyle JF, Garfield B, et al. Pulmonary angiopathy in severe COVID-19: physiologic, imaging, and hematologic observations. Am J Respir Crit Care Med. 2020;202(5):690-9.
18. Jollow DJ, Bradshaw TP, McMillan DC. Dapsone-induced hemolytic anemia. Drug Metab Rev. 1995;27(1-2):107-24.
19. Coleman M, Rhodes L, Scott A, Verbov J, Friedmann P, Breckenridge A, et al. The use of cimetidine to reduce dapsone‐dependent methaemoglobinaemia in dermatitis herpetiformis patients. Br J Clin Pharmacol. 1992;34(3):244-9.
20. Madke B, Kumar P, Kabra P, Singh AL. How to manage a side effect: dapsone-induced methemoglobinemia. Indian J Drugs Dermatol. 2016;2(2):117.
21. Kanwar B, Sergi C, Lee J-h, Kast RE. Hunt regional medical center policy for dapsone administration of ARDS by SARS-CoV-2. OSF Prepr2020.
22. Khattak A, Kanwar B, Sergi C, Lee CJ, Balentine J, Lee JH, et al. Commentary for the Elderly in the Pandemic Era. Dementia and Geriatric Cognitive Disorders Extra. 2021;11(2):168-71.
23. Santos Morais Junior G, Shu Kurizky P, Penha Silva Cerqueira SR, Holanda Barroso D, Schulte HL, Pires de Albuquerque C, et al. Enhanced IL-6 and IL-12B Gene Expression After SARS-CoV-2 Infection in Leprosy Patients May Increase the Risk of Neural Damage. The American journal of tropical medicine and hygiene. 2021.
24. Ackermann M, Verleden SE, Kuehnel M, Haverich A, Welte T, Laenger F, et al. Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in Covid-19. N Engl J Med. 2020;383(2):120-8.
25. Tsang JLY, Binnie A, Fowler RA. Twenty articles that critical care clinicians should read about COVID-19. Intensive Care Med2021.
26. Sinha P, Matthay MA, Calfee CS. Is a “cytokine storm” relevant to COVID-19? JAMA Intern Med. 2020;180(9):1152-4.
27. Marini JJ, Gattinoni L. Management of COVID-19 Respiratory Distress. JAMA. 2020;323(22):2329.
28. Gupta A, Madhavan MV, Sehgal K, Nair N, Mahajan S, Sehrawat TS, et al. Extrapulmonary manifestations of COVID-19. Nat Med. 2020;26(7):1017-32.
29. Song E, Zhang C, Israelow B, Lu-Culligan A, Prado AV, Skriabine S, et al. Neuroinvasion of SARS-CoV-2 in human and mouse brain. J Exp Med. 2021;218(3):e20202135.
30. Lee M-H, Perl DP, Nair G, Li W, Maric D, Murray H, et al. Microvascular injury in the brains of patients with Covid-19. N Engl J Med. 2020;384(5):481-3.
31. Yachou Y, El Idrissi A, Belapasov V, Ait Benali S. Neuroinvasion, neurotropic, and neuroinflammatory events of SARS-CoV-2: understanding the neurological manifestations in COVID-19 patients. Neurol Sci. 2020;41(10):2657-69.
32. Wozel G. Dapson: Pharmakologie, Wirkmechanismus und klinischer Einsatz; 34 Tabellen: Thieme; 1996.
33. Zuidema J, Hilbers-Modderman E, Merkus F. Clinical pharmacokinetics of dapsone. Clin Pharmacokinet. 1986;11(4):299-315.
34. McGeer PL, Harada N, Kimura H, McGeer EG, Schulzer M. Prevalence of dementia amongst elderly Japanese with leprosy: apparent effect of chronic drug therapy. Dement Geriatr Cogn Disord. 1992;3(3):146-9.
35. Namba Y, Kawatsu K, Izumi S, Ueki A, Ikeda K. Neurofibrillary tangles and senile plaques in brain of elderly leprosy patients. Lancet. 1992;340(8825):978.
36. Endoh M, Kunishita T, Tabira T. No effect of anti-leprosy drugs in the prevention of Alzheimer’s disease and β-amyloid neurotoxicity. J Neurol Sci. 1999;165(1):28-30.
37. Meinhardt J, Radke J, Dittmayer C, Franz J, Thomas C, Mothes R, et al. Olfactory transmucosal SARS-CoV-2 invasion as a port of central nervous system entry in individuals with COVID-19. Nat Neurosci. 2020;24(2):168-75.
38. Dey J, Alam MT, Chandra S, Gupta J, Ray U, Srivastava AK, et al. Neuroinvasion of SARS‐CoV‐2 may play a role in the breakdown of the respiratory center of the brain. J Med Virol: Wiley; 2020.
39. Briguglio M, Bona A, Porta M, Dell'Osso B, Pregliasco FE, Banfi G. Disentangling the hypothesis of host dysosmia and SARS-CoV-2: the bait symptom that hides neglected neurophysiological routes. Front Physiol. 2020;11:671.
40. Hoffmann M, Kleine-Weber H, Schroeder S, Kruger N, Herrler T, Erichsen S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020;181(2):271-80.e8.
41. Cantuti-Castelvetri L, Ojha R, Pedro LD, Djannatian M, Franz J, Kuivanen S, et al. Neuropilin-1 facilitates SARS-CoV-2 cell entry and infectivity. Science. 2020;370(6518):856-60.
42. Davies J, Randeva H, Chatha K, Hall M, Spandidos D, Karteris E, et al. Neuropilin1 as a new potential SARSCoV2 infection mediator implicated in the neurologic features and central nervous system involvement of COVID19. Mol Med Rep. 2020;22(5):4221-6.
43. Daly JL, Simonetti B, Klein K, Chen K-E, Williamson MK, Antón-Plágaro C, et al. Neuropilin-1 is a host factor for SARS-CoV-2 infection. Science. 2020;370(6518):861-5.
44. Coquel F, Silva M-J, Técher H, Zadorozhny K, Sharma S, Nieminuszczy J, et al. SAMHD1 acts at stalled replication forks to prevent interferon induction. Nature. 2018;557(7703):57-61.
45. Gatti G, Hossein J, Malena M, Cruciani M, Bassetti M. Penetration of dapsone into cerebrospinal fluid of patients with AIDS. J Antimicrob Chemother. 1997;40(1):113-5.
46. Rich JD, Mirochnick M. Dapsone penetrates cerebrospinal fluid during Pneumocystis carinii pneumonia prophylaxis. Diagn Microbiol Infect Dis. 1996;24(2):77-9.
47. Nau R, SöRgel F, Eiffert H. Penetration of drugs through the blood-cerebrospinal fluid/blood-brain barrier for treatment of central nervous system infections. Clin Microbiol Rev. 2010;23(4):858-83.
48. Varadarajan S, Yatin S, Kanski J, Jahanshahi F, Butterfield DA. Methionine residue 35 is important in amyloid β-peptide-associated free radical oxidative stress. Brain Res Bull. 1999;50(2):133-41.
49. Vogt W. Oxidation of methionyl residues in proteins: tools, targets, and reversal. Free Radic Biol Med. 1995;18(1):93-105.
50. Enache TA, Oliveira-Brett AM. Alzheimer's disease amyloid beta peptides in vitro electrochemical oxidation. Bioelectrochemistry. 2017;114:13-23.
51. Francioso A, Baseggio Conrado A, Blarzino C, Foppoli C, Montanari E, Dinarelli S, et al. One- and two-electron oxidations of β-Amyloid25-35 by carbonate radical anion (CO3•−) and peroxymonocarbonate (HCO4−): role of sulfur in radical reactions and peptide aggregation. Molecules. 2020;25(4):961.
52. De Cesare V, Lopez DC, Mabbitt PD, Fletcher AJ, Soetens M, Antico O, et al. Deubiquitinating enzyme amino acid profiling reveals a class of ubiquitin esterases. Proc Natl Acad Sci U S A. 2021;118(4):e2006947118.
53. Clague MJ, Urbe S, Komander D. Breaking the chains: deubiquitylating enzyme specificity begets function. Nat Rev Mol Cell Biol. 2019;20(6):338-52.
54. Burslem GM, Crews CM. Proteolysis-targeting chimeras as therapeutics and tools for biological discovery. Cell. 2020;181(1):102-14.
55. Chakraborty A, Panda AK, Ghosh R, Biswas A. DNA minor groove binding of a well known anti-mycobacterial drug dapsone: a spectroscopic, viscometric and molecular docking study. Arch Biochem Biophys. 2019;665:107-13.
56. Costello F, Dalakas MC. Cranial neuropathies and COVID-19. Neurology. 2020;95(5):195-6.
57. Nishizawa T, Kawakami A, Taguchi T, Osugi Y. Transient global amnesia with bilateral hippocampal lesions during the COVID‐19 global outbreak. J Gen Fam Med2020.
58. Sutter R, Hert L, De Marchis GM, Twerenbold R, Kappos L, Naegelin Y, et al. Serum neurofilament light chain levels in the intensive care unit: comparison between severely ill patients with and without COVID‐19. Ann Neurol2020.
59. Rajendran ND, Mookan N, Samuel I, Mookan SB, Munusamy G, Gurudeeban S, et al. A theoretical study of chemical bonding and topological and electrostatic properties of the anti-leprosy drug dapsone. J Mol Model. 2020;26(6):138.
60. Mendes AP, Schalcher TR, Barros TG, Almeida ED, Maia CS, Barros CA, et al. A geometric and electronic study of dapsone. J Comput Theor Nanosci. 2011;8(8):1428-31.
61. Ruggiano A, Ramadan K. DNA–protein crosslink proteases in genome stability. Communications Biology. 2021;4(1):11.
62. Ghodke PP, Gonzalez-Vasquez G, Wang H, Johnson KM, Sedgeman CA, Guengerich FP. Enzymatic bypass of an N6-deoxyadenosine DNA–ethylene dibromide–peptide cross-link by translesion DNA polymerases. Journal of Biological Chemistry. 2021;296:100444.
63. Zuo Y, Yalavarthi S, Shi H, Gockman K, Zuo M, Madison JA, et al. Neutrophil extracellular traps in COVID-19. JCI Insight. 2020;5(11).
64. Schmitz V, dos Santos JB. COVID-19, leprosy, and neutrophils. PLOS Neglected Tropical Diseases. 2021;15(1):e0009019.
65. Kanwar B, Lee CJ, Lee J-H. Specific Treatment Exists for SARS-CoV-2 ARDS. Vaccines. 2021;9(6):635.
66. Kast RE, Lefranc F, Karpel-Massler G, Halatsch ME. Why dapsone stops seizures and may stop neutrophils’ delivery of VEGF to glioblastoma. Br J Neurosurg. 2012;26(6):813-7.
67. Salehzadeh F, Jahangiri S, Mohammadi E. Dapsone as an alternative therapy in children with familial mediterranean fever. Iran J Pediatr. 2012;22(1):23.
68. Troili F, Cipollini V, Moci M, Morena E, Palotai M, Rinaldi V, et al. Perivascular unit: this must be the place. the anatomical crossroad between the immune, vascular and nervous system. Front Neuroanat. 2020;14:17.
69. Baig AM. Computing the effects of SARS-CoV-2 on respiration regulatory mechanisms in COVID-19. ACS Chem Neurosci. 2020;11(16):2416-21.
70. Dhont S, Derom E, Van Braeckel E, Depuydt P, Lambrecht BN. The pathophysiology of ‘happy’ hypoxemia in COVID-19. Respir Res. 2020;21(1):198.